Literature DB >> 10894372

The management of pelvic chondrosarcoma in Japan. Japanese Musculo-Skeletal Oncology Group.

K Mochizuki1, H Yamaguchi, T Umeda.   

Abstract

A review of 135 patients with pelvic chondrosarcoma who had been treated at 58 institutions in Japan between 1989 and 1998. In this series ablative surgery was necessary in 14 patients, and a limb salvage procedure performed in 121 patients. The surgical margins were "intra-lesional" in 27 patients, "marginal" in 30, "wide" in 77 and "unspecified" in 1. Local recurrence occurred in 33 patients and distant metastases in 25. Post-operative infection occurred in 25 patients. Revision was performed in 10 patients. The oncological outcome was "disease free" in 92 patients, "alive with disease" in 17 and "dead because of the disease" in 26. The cumulative prospective 10-year survival rate for all patients was 65%. The 6 statistically significant prognostic factors that determined the outcome were: - surgical stage, site of tumour, size of tumour, surgical margin, functional mobility and activity level after surgery. Excision of the tumour with a wide margin, or with a wide margin with partly marginal areas, and subsequent stable reconstruction are essential for improving the results of pelvic chondrosarcoma treatment.

Entities:  

Mesh:

Year:  2000        PMID: 10894372      PMCID: PMC3620591          DOI: 10.1007/s002640000118

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  3 in total

Review 1.  Is it ever safe to discharge a chondrosarcoma of pelvis? Report of a local recurrence after 10 years.

Authors:  Czar Louie L Gaston; Vaiyapuri P Sumathi; Robert J Grimer
Journal:  Musculoskelet Surg       Date:  2012-09-19

Review 2.  [Hemipelvectomy for pelvic sarcomas].

Authors:  W K Guder; J Hardes; M Nottrott; A Streitbürger
Journal:  Orthopade       Date:  2019-09       Impact factor: 1.087

3.  Survival and prognostic factors in conventional central chondrosarcoma.

Authors:  Julian Fromm; Alexander Klein; Andrea Baur-Melnyk; Thomas Knösel; Lars Lindner; Christof Birkenmaier; Falk Roeder; Volkmar Jansson; Hans Roland Dürr
Journal:  BMC Cancer       Date:  2018-08-24       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.